GPN Vaccines

What GPN Vaccines does

GPN Vaccines is a privately held biotechnology company founded in 2017 and headquartered in Adelaide, Australia, focused on developing vaccines against bacterial infections — most notably targeting Streptococcus pneumoniae and bacterial infections associated with Chronic Obstructive Pulmonary Disease (COPD) and pediatric otitis media. The company's core technology centers on proprietary vaccine candidates addressing unmet medical needs in respiratory and pediatric infectious disease, with the pipeline materially expanded in October 2025 through the acquisition of BacVax Inc., a Phoenix, Arizona-based biotech whose capabilities have been folded into the parent.

The company operates with a small team (11-50 employees) and is led by Professor Tim Hirst, a microbiologist and former Angel Investor of the Year serving as CEO and Chairman, with Lauren Giorgio as Chief Operating Officer and Dr. Manon Cox as Director. GPN is pre-revenue and its planned commercial model is licensing and royalties, with no current commercial products or pricing established. Capital has been raised through a series of venture funding rounds led predominantly by Forepont Capital Partners (cumulative disclosed funding of approximately $24.6 million from 2017 through 2024), supplemented by non-dilutive grants from the Government of South Australia and the National Health and Medical Research Council (NHMRC).

The strategic posture is that of a clinical-stage biotech pivoting toward a multi-asset pipeline builder through inorganic growth, evidenced by the BacVax acquisition and an accelerating venture funding cadence. Geographic reach currently encompasses Australia and, post-BacVax, the United States. CEO commentary has flagged potential relocation risk tied to proposed changes in Australia's R&D tax incentive and capital gains tax framework. Distribution channels, certifications, and manufacturing partnerships have not been disclosed, consistent with pre-commercial stage operations.

Name

GPN Vaccines

Legal name

GPN Vaccines Inc.

Website

https://gpnvaccines.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

GPN Vaccines is a privately held Adelaide, Australia-based biotechnology company founded in 2017 that develops vaccines against bacterial infections, including Streptococcus pneumoniae and bacterial infections linked to COPD and pediatric otitis media, with a pre-revenue licensing-based business model and a pipeline expanded via the 2025 acquisition of BacVax Inc.

Ownership category

akta.pro rank

Product category

Vaccines

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Pediatric Vaccines (HLAIAEAA), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Vaccine development
• Bacterial infection vaccines
• Biopharmaceutical research
• Infectious disease prevention
• Streptococcal disease vaccines

Headquarters

HQ city

Adelaide

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Vaccine Development and Commercialization: GPN Vaccines develops and plans to commercialize vaccines targeting bacterial infections such as COPD and otitis media in children. The company is pre-revenue as it focuses on expanding its pipeline through acquisitions like BacVax Inc.

Marketing channels2 records

Core offering

GPN Vaccines is a biotechnology company developing vaccines against bacterial infections, with a primary focus on a Streptococcus pneumoniae vaccine to prevent pneumococcal disease. Through its 2025 acquisition of BacVax Inc., the company expanded its pipeline to include vaccines targeting bacterial infections associated with COPD in adults and otitis media (middle ear infection) in children.

Product overview

GPN Vaccines is a biotechnology company focused on vaccine development. The company operates a unified vaccine development pipeline that was recently expanded through the acquisition of BacVax Inc., a Phoenix-based biotechnology company. The acquired company brings expertise in vaccines targeting bacterial infections, specifically those causing COPD and otitis media in children.

Differentiator

Problem solved

Functional benefit

Products and services

• Streptococcus pneumoniae Vaccine (GPN) A vaccine candidate in development by GPN Vaccines to prevent the spread and impact of Streptococcus pneumoniae (pneumococcus), a major bacterial pathogen. Targeted at healthcare systems, public health agencies, and pharmaceutical licensing partners for population immunization use.
• BacVax Bacterial Infection Vaccine Pipeline (COPD & Otitis Media) Vaccine candidates, acquired via BacVax Inc. (Phoenix, Arizona), targeting bacterial infections associated with Chronic Obstructive Pulmonary Disease (COPD) in adults and elderly patients and otitis media (middle ear infections) in pediatric patients. Intended for licensing or institutional procurement by pharmaceutical and public health buyers.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• BacVax Inc.coreStrategic or Co-development Partner · 27 October 2025GPN Vaccines Inc completed acquisition of BacVax Inc., a biotechnology company based in Phoenix, Arizona. The acquisition aims to expand GPN's vaccine development pipeline, specifically targeting bacterial infections related to COPD and otitis media in children. This acquisition represents a core strategic expansion of GPN's product pipeline through inorganic growth.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vaxcyte: Vaxcyte is a clinical-stage biotech developing pneumococcal conjugate vaccines (VAX-24, VAX-31) targeting the same Streptococcus pneumoniae pathogen space as GPN Vaccines, with a cell-free platform and an analogous pre-revenue development stage.

Emerging players

• Inventprise: Inventprise is a privately held vaccine developer building a pipeline that includes pneumococcal vaccines using a proprietary conjugation platform, comparable to GPN as a small, privately funded infectious-disease vaccine biotech.
• Affinivax: Affinivax developed a Multiple Antigen Presenting System (MAPS) vaccine platform and advanced a pneumococcal candidate before being acquired by GSK; it is comparable to GPN as a peer pneumococcal-vaccine biotech before/around its exit.
• Matrivax: Matrivax is developing a proprietary pathogen-like particle (PLP) vaccine platform with pneumococcal applications, making it a technology-platform peer for GPN's antibacterial vaccine development efforts.

Broad incumbents

• Pfizer (Prevnar franchise): Pfizer's Prevnar 13/20/Prevnar family is the global standard-of-care for pneumococcal vaccination, directly competing with any new pneumococcal entrant including GPN and defining the bar GPN must clear clinically and commercially.
• Merck: Merck markets Pneumovax 23 and Vaxneuvance (PCV15/PCV20 family), making it a primary incumbent in the pneumococcal space and the most direct large-cap competitor to any GPN vaccine program.
• GSK: GSK sells Synflorix (PCV10) globally and acquired Affinivax to expand its pneumococcal pipeline, making it both a competitor and a likely strategic-acquirer profile relative to GPN Vaccines.
• Sanofi Pasteur: Sanofi Pasteur has a historical pneumococcal franchise and broad infectious-disease vaccine infrastructure that competes with and could absorb assets similar to GPN's pipeline.

Regional players

• SK bioscience: SK bioscience is a Korean vaccine developer with a pneumococcal conjugate vaccine (SKYPneumo) advancing through licensure, comparable to GPN as a non-US, regionally anchored pneumococcal-vaccine biotech.

Others

• Novavax: Novavax is a recombinant-protein vaccine developer where GPN director Manon Cox previously held operating leadership; it is adjacent rather than directly competing, but reflects the type of platform/markets mix relevant to GPN's commercialization profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/GPNVaccines

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GPN Vaccines